SCHEMBL5205891

SCHEMBL5205891

COc1ccccc1NC(=O)Nc1cc(C)c(Oc2ccnc3cc(OCCN4CCOCC4)c(OC)cc23)cc1C

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 5/20 0.59
MET P08581 11/20 0.55
KDR P35968 3/20 0.55
EGFR P00533 3/20 0.54
MAPK13 O15264 2/20 0.54
MAPK12 P53778 2/20 0.54
MAPK11 Q15759 2/20 0.54
MAPK14 Q16539 2/20 0.54
PDGFRA P16234 2/20 0.54
FGFR2 P21802 2/20 0.54
AXL P30530 2/20 0.54
PLK4 O00444 1/20 0.54
STK25 O00506 1/20 0.54
CIT O14578 1/20 0.54
AURKA O14965 1/20 0.54
CHUK O15111 1/20 0.54
MUSK O15146 1/20 0.54
EPHB6 O15197 1/20 0.54
MAP3K13 O43283 1/20 0.54
DAPK3 O43293 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5208075 0.90 FLT3 (0.56) FLT3METKDREGFRMAPK13
SCHEMBL5201528 0.90 MET (0.61) FLT3METKDREGFRMAPK13
SCHEMBL5824601 0.87 KDR (0.56) FLT3METKDREGFRMAPK13
SCHEMBL5824505 0.86 FLT3 (0.54) FLT3METKDREGFRMAPK13
SCHEMBL5208131 0.86 PDGFRA (0.61) FLT3METKDRPDGFRAFGFR2
SCHEMBL5201453 0.85 PDGFRA (0.70) KDRPDGFRAFGFR2AXLKIT
SCHEMBL5824454 0.84 FLT3 (0.60) FLT3METKDREGFRMAPK13
SCHEMBL5202939 0.82 PDGFRA (0.61) METKDREGFRPDGFRAFGFR2
SCHEMBL5240346 0.80 PDGFRA (0.74) METKDRPDGFRAFGFR2AXL
SCHEMBL3896869 0.80 SRC (0.69) FLT3METKDREGFRMAPK13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1384712-B1 Derivatives of N-((quinolinyl)oxy)-phenyl)-urea and N-((quinazolinyl)oxy)-phenyl)-urea with antitumor activity KIRIN BREWERY (JP) 2007-03-07 EP disclosed
US-20070027318-A1 Quinoline derivatives and quinazoline derivatives KIRIN BEER KABUSHIKI KAISHA (JP) 2007-02-01 US disclosed
US-7169789-B2 Quinoline derivatives and quinazoline derivatives KIRIN BEER KABUSHIKI KAISHA (JP) 2007-01-30 US disclosed
US-20040209905-A1 Quinoline derivatives and quinazoline derivatives KIRIN BEER KABUSHIKI KAISHA (JP) 2004-10-21 US disclosed
US-6797823-B1 Quinoline derivatives and quinazoline derivatives KIRIN BEER KABUSHIKI KAISHA (JP) 2004-09-28 US disclosed
EP-1384712-A1 Derivatives of N-((quinolinyl)oxy)-phenyl)-urea and N-((quinazolinyl)oxy)-phenyl)-urea with antitumor activity KIRIN BEER KABUSHIKI KAISHA (JP) 2004-01-28 EP disclosed
EP-1153920-B1 QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES KIRIN BREWERY (JP) 2003-10-29 EP disclosed
EP-1153920-A1 QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES KIRIN BEER KABUSHIKI KAISHA (JP) 2001-11-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027318-A1 Quinoline derivatives and quinazoline derivatives CYTH3, NQO2, NRAS FLT3 124/4885MET 2097/4885KDR 2466/4885
US-20040209905-A1 Quinoline derivatives and quinazoline derivatives RABL3, NRAS, CYTH3 FLT3 292/4885MET 2063/4885KDR 3106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.